Sarki Abdulkadir Profile
Sarki Abdulkadir

@SarkiAbdulkadi1

Followers
298
Following
160
Media
0
Statuses
68

Grayhack Professor of Urological Research, Northwestern University @NUFeinbergMed @LurieCancer

Chicago, IL
Joined October 2019
Don't wanna be here? Send us removal request.
@NUFeinbergMed
Northwestern Feinberg School of Medicine
1 year
In this episode of our #BreakthroughsPodcast, @SarkiAbdulkadi1 discusses the discovery of compounds that block the 'undruggable' MYC gene, making #ProstateCancer tumors sensitive to hormone therapy. 🔗 https://t.co/yDtegNPBDs
1
6
23
@rz_yara
Yara Rodriguez Zabala
2 years
I am thrilled to announce that I've been selected as an HHMI Hanna H. Gray Fellow. It's an absolute honor to be part of this amazing community. Huge thanks to my postdoc mentor @KStegmaier_DFCI, PhD advisor, @SarkiAbdulkadi1, and my colleagues @DanaFarberNews and @NUFeinbergMed!
@HHMINEWS
HHMI
2 years
🎉 Today we're thrilled to announce our 2023 #HannaGrayFellows! Please join us in welcoming and celebrating these outstanding early career scientists! Learn more: https://t.co/SAICbjGRvP
8
7
148
@LurieCancer
Lurie Cancer Center
2 years
Congratulations to @LurieCancer’s Mario Shields, PhD, named one of the country’s first 11 @theNCI Cancer Moonshot Scholars! Learn more about his research and the program: https://t.co/SCyEhnatLl #PancreaticCancer
1
5
26
@GaryESchiltz
Gary Schiltz
3 years
Great presentation by ⁦@SarkiAbdulkadi1⁩ discussing our MYC inhibitor project. Very exciting to see this work discussed with the biotech/VC community.
0
1
11
@Mike_C_Burns
Michael Burns, MD-PhD
3 years
@SarkiAbdulkadi1 in his element. 😍
@GaryESchiltz
Gary Schiltz
3 years
Great presentation by ⁦@SarkiAbdulkadi1⁩ discussing our MYC inhibitor project. Very exciting to see this work discussed with the biotech/VC community.
0
1
2
@OUP_VC
Osage Univ. Partners
3 years
We're excited to share #Science2StartupSpotlight @SarkiAbdulkadi1, MD, PhD, Professor of Urology & Pathology, @NorthwesternU. Sarki's presentation will focus on small molecule MYC inhibitors leveraging unique insights into MYC structure and function. Follow along for updates!
0
1
15
@LurieCancer
Lurie Cancer Center
3 years
Please join us in congratulating Mario Shields, PhD, on receiving the Lurie Cancer Center Diversity Scholars Award! This inaugural award will actively support his research aimed at understanding pancreatic cancer development and progression. Learn more: https://t.co/26OFoHfqpK
1
5
19
@LurieCancer
Lurie Cancer Center
3 years
Today’s annual Members Retreat led off with updates on our impact from @LurieCancer Director, @LeonidasPlatan1, and Associate Director of Diversity, Equity & Inclusion, @SarkiAbdulkadi1 — followed by breakout sessions to discuss our progress and learn from each other.
0
4
20
@Mike_C_Burns
Michael Burns, MD-PhD
3 years
Congrats!! TACTICAL Award from @PCFnews to my mentors and academic bestie at @LurieCancer !! @SarkiAbdulkadi1 @GaryESchiltz Maha Hussain and Sarah Fenton Congrats to @ArulChinnaiyan and the UMich team too.
@LurieCancer
Lurie Cancer Center
3 years
Congratulations to @LurieCancer investigators for receiving an inaugural @PCFNews TACTICAL Award! @SarkiAbdulkadi1 is a PI of the $4M grant to develop an effective inhibitor of MYC, a critical driver of #prostatecancer development. https://t.co/Xr82RocESo #pcsm
1
1
18
@Mike_C_Burns
Michael Burns, MD-PhD
3 years
Nice work and years of dedication by @LauraSoucek @peptomyc. So glad to see Omomyc in the clinic. Also, very happy to see @SarkiAbdulkadi1 @LurieCancer work advancing small molecules myc inhibitors to clinic. MYC is not "undruggable", it's just "not drugged yet"
@NatRevDrugDisc
Nature Reviews Drug Discovery
3 years
Climbing cancer’s MYC mountain https://t.co/OqObZtXICa MYC, one of the most commonly dysregulated proteins in cancer, has long seemed ‘undruggable’. Can a clinical-stage cell-penetrating peptide — or preclinical small-molecule inhibitors and degraders — prove otherwise?
0
2
7
@slava__bobrov
Slava Bobrov
3 years
Fish in a drop of water on a lotus leaf: #biology
149
2K
17K
@FDAOncology
FDA Oncology
3 years
An opportunity for early-stage investigators from underrepresented groups. #diversity #CancerResearch #CancerMoonshot
0
2
1
@NM_Urology
NM Urology
3 years
The Polsky Urologic Cancer Institute of the @LurieCancer of @NorthwesternU at NMH has chosen six faculty members to receive the Research Award to support clinical, laboratory or translational projects to advance knowledge & innovative research in the field of urologic #oncology.
1
4
21
@LurieCancer
Lurie Cancer Center
3 years
A MYC inhibitor operates selectively, reducing expression of genes that fuel cell proliferation and alter the #epigenome, according to Drs. Debabrata Chakravarti & @SarkiAbdulkadi1 @LurieCancer, co-senior authors of the study in @ScienceAdvances https://t.co/aOlb0PAXi9
0
1
14
@dgpnorthwestern
Driskill Graduate Program in Life Sci
4 years
Congratulations, Yara Rodriguez, PhD, on her final thesis! 🥳
0
1
7
@LurieCancer
Lurie Cancer Center
4 years
On Fri., May 13, hear from Richard Pazdur, MD, Director of @FDAOncology, and an expert panel from @LurieCancer on “Drug Development from Bench to Bedside.” View the agenda and register for our 2022 TRIST Symposium on @NorthwesternU’s Chicago campus at: https://t.co/URbTcHvsAT
1
2
6
@HarmonyTurk
Harmony Turk
4 years
“A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer” is online today in @CR_AACR and being presented at #AACR22 now. Visit @rz_yara at the poster (Section 16 Board 7) and read the article! https://t.co/bcgZ3JIzKx
0
7
14
@ScienceMagazine
Science Magazine
4 years
In South Korea, mandatory wearing of masks and practicing social distancing with masks on public transport during peak hours reduced infection rates by 93.5 and 98.1%, respectively, according to a new modeling study in @ScienceAdvances. https://t.co/4QvvyMTsQn
13
201
490